The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the latest update on pancreatic cancer research. Pancreatic cancer remains one of the most lethal human malignancies: median survival after diagnosis is typically measured in months, and the f ...